Bipolar Psychopharmacotherapy
Bipolar Psychopharmacotherapy Caring for the Patient
Second Edition

Edited by

Hagop S. Akiskal
University of California, San Diego, CA, USA

and

Mauricio Tohen
Department of Psychiatry,
University of Texas Health Science Centre, San Antonio, TX, USA
International Society for Bipolar Disorders

WILEY-BLACKWELL
A John Wiley & Sons, Ltd., Publication
This book is dedicated to patients with bipolar disorder and their families for the privilege of caring for them.

We also dedicate it to Pierre Deniker and Mogens Schou for their pioneering research which made such caring possible.

“To my wife Dianne” — Mauricio Tohen
Contents

List of Contributors xv

Preface to the Second Edition xxv

Chapter 1 The scope of bipolar disorders 1
Hagop S. Akiskal
1.1 Diagnostic and public health aspects 1
1.2 Psychological and social aspects 4
Appendix 1.A: Laboratory considerations in the clinical use of lithium 5
References 6

Chapter 2 Lithium treatment: Focus on long-term prophylaxis 9
Paul Grof and Mogens Schou
2.1 Introduction 9
2.2 Cade’s pioneering study 10
2.3 Discovery of the prophylactic action of lithium 10
2.4 Practical issues 13
2.5 Are new and better prophylactic agents about to oust lithium? 16
2.6 Combination treatment 17
2.7 Prophylaxis in recurrent depressive disorder 17
2.8 The effect of lithium on the patients’ suicidal behavior 18
2.9 Benefits of prophylactic lithium treatment 18
2.10 Conclusion 19
References 19

Chapter 3 Valproate: Clinical pharmacological profile 25
Charles L. Bowden and Vivek Singh
3.1 Historical background 25
3.2 Structure–activity relationships 25
3.3 Pharmacodynamic properties 26
3.4 Pharmacokinetics and metabolic clearance 27
3.5 Serum concentration and efficacy 28
3.6 Efficacy and indications 28
3.7 Efficacy in bipolar disorder 28
3.8 Combination strategy in acute mania 30
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.9</td>
<td>Prophylaxis in bipolar disorder</td>
<td>30</td>
</tr>
<tr>
<td>3.10</td>
<td>Treatment of bipolar depression</td>
<td>31</td>
</tr>
<tr>
<td>3.11</td>
<td>Valproate in treatment of bipolar disorder in children and adolescents</td>
<td>32</td>
</tr>
<tr>
<td>3.12</td>
<td>Use in bipolar illness comorbid with alcoholism</td>
<td>33</td>
</tr>
<tr>
<td>3.13</td>
<td>Bipolar disorder comorbid with ADHD</td>
<td>33</td>
</tr>
<tr>
<td>3.14</td>
<td>Bipolar disorder comorbid with borderline personality disorder</td>
<td>34</td>
</tr>
<tr>
<td>3.15</td>
<td>Adverse effects</td>
<td>34</td>
</tr>
<tr>
<td>3.16</td>
<td>Comparative adverse effects</td>
<td>34</td>
</tr>
<tr>
<td>3.17</td>
<td>Adverse effects in combination therapy, compared with monotherapy</td>
<td>34</td>
</tr>
<tr>
<td>3.18</td>
<td>Adverse effects by bodily system</td>
<td>35</td>
</tr>
<tr>
<td>3.19</td>
<td>Summary</td>
<td>38</td>
</tr>
</tbody>
</table>

Chapter 4  Pharmacological profile and clinical utility of lamotrigine in mood disorders
Marc L.M. van der Loos, Joseph R. Calabrese, Willem A. Nolen and David J. Muzina

4.1 Introduction | 45
4.2 Clinical pharmacology of lamotrigine | 46
4.3 Lamotrigine and mood disorders | 47
4.4 Safety | 52
4.5 Clinical applications for lamotrigine in mood disorders | 54
4.6 Summary | 57

Chapter 5  Carbamazepine and other anticonvulsants
Heinz Grunze

5.1 Introduction | 61
5.2 Conclusions | 69

Chapter 6  Olanzapine in treatment for bipolar disorder
Mauricio Tohen, Giedra Campbell and Juan-Carlos Gómez

6.1 Introduction | 79
6.2 Rationale in the clinical trial development of olanzapine | 80
6.3 Efficacy in the treatment of acute mania | 81
6.4 Efficacy in the treatment of bipolar depression | 89
6.5 Efficacy in bipolar maintenance/relapse prevention | 92
6.6 Safety and tolerability | 95
6.7 Summary | 104

References

Chapter 4  Pharmacological profile and clinical utility of lamotrigine in mood disorders
Marc L.M. van der Loos, Joseph R. Calabrese, Willem A. Nolen and David J. Muzina

4.1 Introduction | 45
4.2 Clinical pharmacology of lamotrigine | 46
4.3 Lamotrigine and mood disorders | 47
4.4 Safety | 52
4.5 Clinical applications for lamotrigine in mood disorders | 54
4.6 Summary | 57

Chapter 5  Carbamazepine and other anticonvulsants
Heinz Grunze

5.1 Introduction | 61
5.2 Conclusions | 69

Chapter 6  Olanzapine in treatment for bipolar disorder
Mauricio Tohen, Giedra Campbell and Juan-Carlos Gómez

6.1 Introduction | 79
6.2 Rationale in the clinical trial development of olanzapine | 80
6.3 Efficacy in the treatment of acute mania | 81
6.4 Efficacy in the treatment of bipolar depression | 89
6.5 Efficacy in bipolar maintenance/relapse prevention | 92
6.6 Safety and tolerability | 95
6.7 Summary | 104

References

Chapter 7 Haloperidol and other first generation antipsychotics in mania

John Cookson

7.1 Introduction
7.2 Acute tranquillization in mania
7.3 Sedation is not required for antipsychotics to improve mania
7.4 Chlorpromazine in mania
7.5 Haloperidol in mania
7.6 Hormone changes and mechanisms of antimanic effects of antipsychotics
7.7 Antipsychotics as mood stabilizers
7.8 Placebo-controlled studies in mania
7.9 Recent comparative trials without placebo
7.10 Pharmacoeconomics
7.11 Conclusions
Declaration of interest
References

Chapter 8 Clinical utility of clozapine in bipolar disorder

V.E. Cosgrove, J.S. Seo, H. Yang and Trisha Suppes

8.1 Introduction
8.2 History
8.3 Clinical pharmacology of clozapine
8.4 Clozapine in bipolar disorders
8.5 Effective pharmacotherapy for bipolar disorder?
8.6 Case studies
References

Chapter 9 Risperidone and paliperidone in the treatment of bipolar disorder

L. Ivo Caers and Joris Berwaerts

9.1 Introduction
9.2 Oral risperidone in bipolar mania
9.3 Paliperidone extended release (ER) in bipolar mania
9.4 Risperidone long-acting injectable (LAI) in the maintenance treatment of bipolar disorder
9.5 Elements of special interest
9.6 Summary and conclusions
References
Contents

13.3 Human pharmacokinetics 273
13.4 Asenapine: Efficacy in bipolar mania and mixed states 274
13.5 Asenapine: Efficacy and tolerability during extension treatment 279
13.6 Summary and conclusion 281
References 282

Chapter 14 Complex combination therapy for long-term stability in bipolar disorder 285
Robert M. Post
14.1 Introduction 285
14.2 Rationale for complex combination therapy in bipolar illness 285
14.3 Principles of building an effective therapeutic regimen 287
14.4 Conclusions 293
References 296

Chapter 15 The role of antidepressants in bipolar disorder 299
Boghos I. Yerevanian
15.1 Introduction 299
15.2 Tricyclic antidepressants 301
15.3 MAO inhibitors 303
15.4 SSRIs 304
15.5 SNRIs: Venlafaxine, mirtazapine, duloxetine 309
15.6 Bupropion 310
15.7 Clinical and research implications 310
References 312

Chapter 16 Bipolarity in women: Therapeutic issues 317
Susan L. McElroy, Lesley M. Arnold and Lori L. Altshuler
16.1 Introduction 317
16.2 Epidemiology and gender distribution of the bipolar spectrum 317
16.3 Gender differences in phenomenology 318
16.4 Gender differences in course and outcome 321
16.5 Gender differences in comorbidity 322
16.6 Bipolar disorder and the reproductive cycle 323
16.7 Treatment of bipolar disorder in females 327
16.8 Summary 337
References 338

Chapter 17 Pediatric bipolar disorder: The promise of psychopharmacotherapy 351
Tiffany Thomas and Robert L. Findling
17.1 Introduction 351
17.2 Lithium 352
17.3 Anticonvulsants 355
17.4 Antipsychotics 359
17.5 Conclusion 365
Disclosures 365
References 365

Chapter 18 Treatment of bipolar disorder in old age 369
Kenneth I. Shulman, Nathan Herrmann and Martha Sajatovic
18.1 Treatment of bipolar disorder in old age 369
18.2 Management of bipolar disorder in the elderly 374
18.3 Treatment of bipolar depression in older adults 378
18.4 The future 382
References 383

Chapter 19 Diagnosis and treatment of mixed states 391
Alan C. Swann
19.1 What is a mixed state? 391
19.2 General considerations for treatment strategies in mixed states 398
19.3 Treating mania in mixed states 399
19.4 Treating depression in mixed states 401
19.5 Nonpharmacological treatments 402
19.6 An Integrated model for treating mixed states 403
19.7 Conclusions 405
References 405

Chapter 20 Rapid cycling of bipolar patients 411
Athanasios Koukopoulos, G. Serra, F. Zazzara, A. E. Koukopoulos and G. Sani
20.1 Introduction 411
20.2 Epidemiological data 411
20.3 Spontaneous and induced rapid cycling 412
20.4 Temperament and rapid cycling 414
20.5 Course 414
20.6 Clinical picture of rapid cycling 415
20.7 Neurobiology of rapid cycling bipolar disorder: The role of dopamine D2 receptors, sensitization 416
20.8 Treatment 417
20.9 Discussion 418
References 420

Chapter 21 Novel therapeutic approaches for treating bipolar disorder 423
Rodrigo Machado-Vieira, Ioline Henter, Jacqueline Baumann, David Latov, Cristina Wheeler-Castillo and Carlos A. Zarate
21.1 Introduction 423
21.2 The dynorphin opioid neuropeptide system 424
21.3 The purinergic system 425
21.4 The melatonergic system 426
21.5 The glutamatergic system 427
21.6 The tachykinin neuropeptides system 430
21.7 The glucocorticoid system 431
21.8 The arachidonic acid (AA) cascade 432
21.9 The endocannabinoid system 433
21.10 Oxidative stress and bioenergetics 434
21.11 The intracellular signaling pathways 435
21.12 Final remarks 436
References 436

Chapter 22 The pivotal role of psycho-education in the long-term treatment of bipolar disorder 447
Francesc Colom and Andrea Murru
22.1 Introduction 447
22.2 On the need for psycho-education 452
22.3 The five ingredients of psycho-education 452
22.4 Substance misuse avoidance 455
22.5 Early warning signs – detection 457
22.6 Lifestyle regularity (and miscellanea) 458
22.7 Psycho-education with the family 460
22.8 Long-term follow-up 460
22.9 The future 461
22.10 Funding sources and acknowledgments 462
References 462

Chapter 23 The role of treatment setting in the pharmacotherapy of bipolar disorder 465
Jean-Michel Azorin
23.1 Implementation of drug treatment according to phase and severity of illness 465
23.2 Pretreatment evaluation and monitoring of pharmacotherapy 466
23.3 Drug response and treatment setting 467
23.4 From efficacy to efficiency of pharmacotherapy in bipolar illness 467
References 468

Chapter 24 Pharmacological prevention of suicide in bipolar patients 471
Zoltán Rihmer
24.1 Introduction 471
24.2 Mood disorders and suicidal behavior 471
24.3 Risk of suicidal behavior in bipolar disorders 472
24.4 Suicide prevention in bipolar disorders 475
References 481